Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 478

1.

Assessing response to interferon-β in a multicenter dataset of patients with MS.

Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group.

Neurology. 2016 Jun 15. pii: 10.1212/WNL.0000000000002830. [Epub ahead of print]

PMID:
27306626
2.

Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies.

Mäurer M, Comi G, Freedman MS, Kappos L, Olsson TP, Wolinsky JS, Miller AE, Dive-Pouletty C, Bozzi S, O'Connor PW.

Mult Scler Relat Disord. 2016 May;7:33-40. doi: 10.1016/j.msard.2016.02.012. Epub 2016 Feb 17.

3.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ.

Mult Scler. 2016 May 19. pii: 1352458516649037. [Epub ahead of print]

PMID:
27207449
4.

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.

Schippling S, O'Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, Cook S, Filippi M, Hartung HP, Comi G, Jeffery DR, Kappos L, Goodin DS, Arnason B.

J Neurol. 2016 May 13. [Epub ahead of print]

PMID:
27177997
5.

Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).

Amann M, Pezold S, Naegelin Y, Fundana K, Andělová M, Weier K, Stippich C, Kappos L, Radue EW, Cattin P, Sprenger T.

J Neurol. 2016 May 9. [Epub ahead of print]

PMID:
27159989
6.

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H.

Neurol Clin Pract. 2016 Apr;6(2):102-115.

7.

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.

Meira M, Sievers C, Hoffmann F, Haghikia A, Rasenack M, Décard BF, Kuhle J, Derfuss T, Kappos L, Lindberg RL.

Neurol Neuroimmunol Neuroinflamm. 2016 Mar 31;3(3):e223. doi: 10.1212/NXI.0000000000000223. eCollection 2016 Jun.

8.

Multiple Sclerosis and Antibodies against KIR4.1.

Pröbstel AK, Kuhle J, Lecourt AC, Vock I, Sanderson NS, Kappos L, Derfuss T.

N Engl J Med. 2016 Apr 14;374(15):1496-8. doi: 10.1056/NEJMc1507131. No abstract available.

PMID:
27074084
9.

Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study.

Fox J, Kraemer M, Schormann T, Dabringhaus A, Hirsch J, Eisele P, Szabo K, Weiss C, Amann M, Weier K, Naegelin Y, Kappos L, Gass A.

Int J Mol Sci. 2016 Apr 1;17(4). pii: E489. doi: 10.3390/ijms17040489.

10.

Power estimation for non-standardized multisite studies.

Keshavan A, Paul F, Beyer MK, Zhu AH, Papinutto N, Shinohara RT, Stern W, Amann M, Bakshi R, Bischof A, Carriero A, Comabella M, Crane JC, D'Alfonso S, Demaerel P, Dubois B, Filippi M, Fleischer V, Fontaine B, Gaetano L, Goris A, Graetz C, Gröger A, Groppa S, Hafler DA, Harbo HF, Hemmer B, Jordan K, Kappos L, Kirkish G, Llufriu S, Magon S, Martinelli-Boneschi F, McCauley JL, Montalban X, Mühlau M, Pelletier D, Pattany PM, Pericak-Vance M, Cournu-Rebeix I, Rocca MA, Rovira A, Schlaeger R, Saiz A, Sprenger T, Stecco A, Uitdehaag BM, Villoslada P, Wattjes MP, Weiner H, Wuerfel J, Zimmer C, Zipp F; International Multiple Sclerosis Genetics Consortium. Electronic address: AIVINSON@PARTNERS.ORG, Hauser SL, Oksenberg JR, Henry RG.

Neuroimage. 2016 Jul 1;134:281-94. doi: 10.1016/j.neuroimage.2016.03.051. Epub 2016 Apr 1.

11.

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.

Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue EW, Sprenger T, Stippich C, Derfuss T, Louvion JF, Kamm CP, Mattle HP, Lotter C, Du Pasquier R, Schluep M, Pot C, Lalive PH, Yaldizli Ö, Gobbi C, Kappos L, Kuhle J; SMSC Scientific Board.

PLoS One. 2016 Mar 31;11(3):e0152347. doi: 10.1371/journal.pone.0152347. eCollection 2016.

12.

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy.

Rust H, Kuhle J, Kappos L, Derfuss T.

Neurol Neuroimmunol Neuroinflamm. 2016 Mar 9;3(2):e215. doi: 10.1212/NXI.0000000000000215. eCollection 2016 Apr. No abstract available.

13.

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas; Teriflunomide Multiple Sclerosis Oral TEMSO Trial Group and the MRI-AC in Houston Texas.

Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10.

14.

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.

Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, O'Connor PW, Benamor M, Dukovic D, Truffinet P, Leist TP.

Mult Scler Relat Disord. 2016 Jan;5:97-104. doi: 10.1016/j.msard.2015.11.006. Epub 2015 Nov 10.

15.

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators.

Lancet. 2016 Mar 12;387(10023):1075-84. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28.

PMID:
26827074
16.

MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.

Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F; MAGNIMS Study Group.

Lancet Neurol. 2016 Mar;15(3):292-303. doi: 10.1016/S1474-4422(15)00393-2. Epub 2016 Jan 26. Review.

PMID:
26822746
17.

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).

Wiendl H, Butzkueven H, Kappos L, Trojano M, Pellegrini F, Paes D, Zhang A, Belachew S; Tysabri® Observational Program (TOP) Investigators.

PLoS One. 2016 Jan 15;11(1):e0144834. doi: 10.1371/journal.pone.0144834. eCollection 2016.

18.

Monitoring multiple sclerosis by multimodal evoked potentials: Numerically versus ordinally scaled scoring systems.

Schlaeger R, Hardmeier M, D'Souza M, Grize L, Schindler C, Kappos L, Fuhr P.

Clin Neurophysiol. 2016 Mar;127(3):1864-71. doi: 10.1016/j.clinph.2015.11.041. Epub 2015 Dec 10.

PMID:
26754876
19.

Efficacy and Safety of Fingolimod in an Unselected Patient Population.

Rasenack M, Rychen J, Andelova M, Naegelin Y, Stippich C, Kappos L, Lindberg RL, Sprenger T, Derfuss T.

PLoS One. 2016 Jan 6;11(1):e0146190. doi: 10.1371/journal.pone.0146190. eCollection 2016.

20.

Quantified CSF antibody reactivity against myelin in multiple sclerosis.

Sun X, Bakhti M, Fitzner D, Schnaars M, Kruse N, Coskun Ü, Kremser C, Willecke K, Kappos L, Kuhle J, Simons M.

Ann Clin Transl Neurol. 2015 Nov 9;2(12):1116-23. doi: 10.1002/acn3.264. eCollection 2015 Dec.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk